Accelerate Diagnostics
360Dx Top 30 Starts the Year up 1 Percent
Of the 30 companies in the index, 22 saw their share prices increase while eight saw stock prices drop.
360Dx Top 30 Drops 37 Percent in 2022
All but one of the 30 companies in the list saw their share prices decline year over year with several firms' stock prices retreating more than 80 percent.
Accelerate Diagnostics Seeks FDA 510(k) Clearance for Expanded Abx Susceptibility Tests
The firm hopes to secure clearance to update its antibiotic susceptibility testing menu, susceptibility breakpoints, and de-escalation options to aid patient discharge.
360Dx Top 30 Grows 8 Percent, Continues Upward Climb
Of the 30 companies in the index, 21 saw their stock prices rise, while nine firms' share prices decreased.
Earnings Roundup: Accelerate Diagnostics, Exagen, Lucira Health, More
Accelerate, Exagen, Lucira, Lucid Diagnostics, and Interpace Biosciences reported their quarterly financial results this week.
Sep 1, 2022
360Dx Top 30 Tumbles in August
Aug 19, 2022
Accelerate Prices $35M Public Stock Offering
Aug 1, 2022
360Dx Top 30 Rebounds in July After June Swoon
Jul 1, 2022
360Dx Top 30 Drops 5 Percent in June
May 17, 2022
May 16, 2022
Accelerate Diagnostics Q1 Revenues Climb 20 Percent
Apr 1, 2022
360Dx Top 30 Falls Slightly in March
Feb 1, 2022
360Dx Top 30 Plummets 17 Percent in January
Sep 22, 2021